Feminizing Hormone Therapy and the Rectal Mucosa Immune Environment in Transgender Women
This study looks at how feminizing hormones affect the rectal area in people who were born male and now take these hormones. Understanding this can improve ways to stop HIV, including making new treatments or vaccines. The study involves 520 transgender women (TGWSM) and cis-gender men who have sex with men.
Participants are divided into two groups. The first group, called a "cross-sectional study," includes 300 TGWSM on hormone therapy and 150 cis-gender men. This group is part of the study for up to 12 weeks. The second group, called a "longitudinal study," includes 70 TGWSM who are starting hormone therapy and will be part of the study for 18 months.
- Participants must be aged 18-59 years, HIV-negative, and able to give consent.
- Involves blood and rectal samples and avoiding certain activities before and after tests.
- Some health conditions or recent medications could disqualify participation.